NRx Pharmaceuticals announces positive safety report for Zyesami in NIH-sponsored ACTIV-3 study in… EP News Bureau Aug 21, 2021 ACTIV-3 Critical Care is evaluating Zyesami and Remdesivir in critical COVID-19 patients as monotherapy, and in combination…
